XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES (Tables)
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contingent Consideration
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the six months ended June 30, 2022 and June 30, 2021 is as follows (in thousands):
Six Months Ended June 30, 2022Contingent Consideration Liability Related to Acquisition of:
Arkis Location in Financial StatementsDerma SciencesACell Inc.
 (See Note 3)
Location in Financial Statements
Short-termLong-termLong-termShort-termLong-term
Balance as of January 1, 2022
$3,691 $11,408 $230 $— $21,800 
Transfers— 4,885 (4,885)
Change in fair value of contingent consideration liabilities (155)$(1,978)Research and development— (4,885)1,219 Selling, general and administrative
Balance as of June 30, 2022$3,536 $9,430 $230 $— $18,134 
Six Months Ended June 30, 2021Contingent Consideration Liability Related to Acquisition of:
ArkisLocation in Financial StatementsDerma SciencesACell Inc.
 (See Note 3)
Location in Financial Statements
Short-termLong-termLong-termLong-term
Balance as of January 1, 2021
$3,415 $11,746 $230 $— 
Additions from acquisition of ACell— — — 23,900 
Transfers(3,432)3,432 — — 
Change in fair value of contingent consideration liabilities17 (402)Research and development— (400)Selling, general and administrative
Balance as of June 30, 2021
$— $14,776 $230 $23,500